The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

This was the stock's second consecutive day of gains.

By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...

CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...

As Bristol gets ready to celebrate Christmas, here is our penultimate round-up of images from across the city for this year. It's pantomime season at our theatres, with varied productions for ...

Cancer-focused CytomX Therapeutics Inc. will lay off 40% of its workforce — about 50 employees — to help extend its cash into ...

Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb ...

By contrast, the most common Cobenfy side effects in clinical trials were somewhat mild by comparison: nausea, indigestion, constipation, vomiting, hypertension, abdominal pain, diarrhea, increased ...